Drugmaker Lupin reported a net profit (profit after tax) of Rs 438.3 crore in the quarter ended December 31 led by growth of sales in the US, India and Rest of the World markets.
The company reported a loss of Rs 835 crore during the corresponding period of the previous year. The net profit doubled on a quarter-on-quarter (QoQ) basis.
Revenues of Lupin rose 5.4 percent year-on-year (YoY) to Rs 3,917.3 crore, compared to previous year's Rs 3716 crore. On a QoQ basis, the revenue rose 3.6 percent.
The EBITDA grew 53 percent YoY to Rs 800 crore in Q3FY21. The EBITDA margin stood at 20.4 percent.